MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.14
-0.03
-0.42%
After Hours: 7.14 0 0.00% 16:30 01/17 EST
OPEN
7.23
PREV CLOSE
7.17
HIGH
7.40
LOW
7.12
VOLUME
467.00K
TURNOVER
--
52 WEEK HIGH
8.49
52 WEEK LOW
1.860
MARKET CAP
591.79M
P/E (TTM)
-4.3362
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ARDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ARDX News

  • How Ardelyx, Inc. (NASDAQ:ARDX) Can Impact Your Portfolio Volatility
  • Simply Wall St..12/31/2019 10:16
  • The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering
  • Benzinga.12/20/2019 13:12
  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.12/05/2019 12:14
  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.12/05/2019 12:14

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ARDX

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
More

Webull offers Ardelyx Inc (ARDX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.